Present IconHave an Alzheimer's or MCI diagnosis?
Receive a free test by participating in our study →
NeuroAge Therapeutics logo
Genetic resilience analysis illustration
APOE + polygenic riskNeuro + broader disease riskUpload or add sequencing

Genetic Resilience Analysis

Genetic Resilience Analysis is NeuroAge's inherited-risk and resilience product, covering Alzheimer's risk, other neurodegenerative disorders, longevity and resilience markers, medically actionable pharmacogenomic genes, broader disease risks, and personalized recommendations based on your genetic profile.

$249

Use qualifying whole-genome data you already have or add genome sequencing at checkout, then review personalized recommendations in the context of your inherited risk profile.

  • Genetic Resilience analysis from existing sequencing data you will provide
  • Interpretation of your scores
  • Personalized recommendations
  • One 30-minute virtual consultation

Optional add ons +

Genome Sequencing

+ $550

Sequence your genome for the Genetic Resilience analysis (30X whole-genome sequencing)

Purchase Genetic Analysis
The Wall Street Journal
Nature Aging
New Scientist
Forbes
eLife
WHY IT MATTERS

Genetics can clarify baseline susceptibility long before symptoms appear

Inherited risk does not determine your future, but it can tell you where to pay closer attention.

NeuroAge uses genetics to help clients understand inherited Alzheimer's risk, other neurodegenerative disorders, protective or longevity-associated variants, medication-relevant genes, and broader disease risks that can matter clinically.

The product is especially useful for people with family history, those who already have sequencing data, or those who want to build a more complete prevention baseline.

Risk

Review APOE status and a broader Alzheimer's polygenic risk score rather than relying on a single gene alone.

Resilience

See longevity and protective variants that can add nuance to your brain-aging profile.

Actionability

Surface medically actionable and pharmacogenomic markers that can be relevant far beyond brain health alone.

BEST FOR

Best for people who want inherited-risk context with more depth than consumer genetics

The genetics page is built for people who want clinical-grade interpretation and broader coverage.

People with family history

Get more detailed inherited-risk information if Alzheimer's or related disease runs in your family.

People with existing sequencing

Put whole-genome data to work with brain-aging and disease-risk interpretation.

People building a fuller baseline

Combine genetics with MRI, biomarkers, or NeuroGames for more complete context.

OUR SCIENCE

APOE is only one part of the genetics story

NeuroAge's science and FAQ materials describe a genetics product that extends well beyond a single Alzheimer's risk allele.

For Alzheimer's, NeuroAge calculates a polygenic risk score across 41 variants rather than reporting APOE alone. The genetics panel also covers broader neurodegenerative markers, protective or longevity-associated genes, and personalized recommendations grounded in the patterns found in your profile.

The same materials also describe medically actionable or pharmacogenomic genes such as MTHFR, CYP2C19, CYP2C9, SLCO1B1, VKORC1, and HLA-B*15:02, along with broader disease-risk areas including coronary artery disease, atrial fibrillation, osteoporosis, colorectal cancer, primary open-angle glaucoma, psoriasis, Crohn's disease, and ovarian cancer.

Included areas

  • APOE status and a 41-variant Alzheimer's polygenic risk score.
  • Broader neurodegenerative and longevity-associated markers including Klotho, FOXO3, CETP, IGF1R, IL-6, mTOR, and PCSK9.
  • Actionable pharmacogenomic and disease-risk genes extending beyond brain aging alone.
RESULTS DASHBOARD

Review inherited risk and resilience in a clearer format

The dashboard helps organize genetic findings into a structure that is easier to discuss and act on.

See Alzheimer's-related findings alongside broader resilience and longevity markers.

Review pharmacogenomic and actionable genes in one place.

Use the dashboard as a bridge into personalized recommendations, coaching, or other NeuroAge products if desired.

NeuroAge genetics results dashboard showing inherited risk, resilience markers, and recommendations

Client Testimonials

What NeuroAge customers are saying across imaging, testing, and coaching.

I live my life profoundly between my ears - I enjoy learning and thinking and reading and writing and making things. The prospect of losing those abilities, and losing the memories that they have created, frightens me.If you have a family history like mine, this assessment can help you better understand your risk of Alzheimer's and how you're doing so far. It can give you the incentive you need to manage your risk more thoughtfully.
Mike OlsonMike Olson
NeuroAge Therapeutics is an amazing and best in class company led by the very best Co-founder and CEO.I have been impressed since day one. They produce positive results and guidance. I unequivocally recommend NeuroAge Therapeutics.
Carol DiBattisteCarol DiBattiste
I've worked with NeuroAge for several years across their full platform - including MRI analysis, genetics, blood biomarkers, cognitive tests and personalised coaching on the key pillars of healthy brain aging.What sets them apart is the integration: a holistic view of where my brain health stands today, drawing together all the available data and tracked over time, combined with a practical framework for what to do about it. The focus is squarely on prevention and the insights are specific, actionable and evidence based.For anyone serious about the cutting edge of preventive brain health, I can't recommend NeuroAge highly enough.
Jamie GarisJamie Garis
The most comprehensive brain health assessment I've ever done — and it may have saved my life.NeuroAge caught a brain aneurysm that Prenuvo missed entirely on THREE scans. That alone made the whole experience worth it. But what really sets NeuroAge apart is the depth of what they actually measure — this isn't just a scan.My assessment combined a brain MRI analyzed across 25 regions, cognitive testing through their NeuroGames platform, blood biomarkers, and whole genome sequencing. Everything feeds into a single NeuroAge score. Mine came back 6 years younger than my chronological age, which puts me in the 80th percentile — but more importantly, I now know exactly which areas to work on (thalamus, white matter, hippocampus) and have a personalized, evidence-based plan to address them.The genetic component is where it gets really interesting — I learned about medically actionable variants that affect how I metabolize certain medications, including a VKORC1 variant relevant to blood thinners and a CYP2C19 variant affecting a range of common drugs. That's information I'll carry to every doctor's appointment.The reporting is thorough, the recommendations are backed by citations, and the level of personalization is unlike anything I've experienced in conventional medicine. If you're serious about proactive brain health, this is where to start.
Laurie ZugayLaurie Zugay
In January I attended the R42 Healthcare Retreat at the Ritz Carlton in Half Moon Bay. Multiple tests were included in the price. The brilliant, Alzheimer trailblazer,Christin Glorioso, M.D. was in charge of coordinating the brain MRI's and other cognitive tests for the retreat through her company, NeuroAge Therapeutics. She founded, to prevent and treat Alzheimer's which had decimated her family. She flagged my brain MRI as abnormal and possible NPH. NPH is a rare condition that affects balance, cognitive decline and urinary incontinance aka “wet, wobbly and wacky.” She contacted me and strongly suggested that I consult with a neurologist and assured me that it was treatable which was a massive relief. But for Dr. Glorioso this rare, treatable condition would have never been found.Thank you Christin for alerting me and staying with me while I went through the testing (including a spinal tap to relieve the spinal tap to release the pressure in my brain) to confirm the diagnosis. This is a rare condition and never would have been discovered but for the brain MRI and the determination of Dr. Glorioso.
Marisa McGinnisMarisa McGinnis
FAQ

Questions, answered

No. NeuroAge's genetics materials describe APOE plus a 41-variant Alzheimer's polygenic risk score, broader neurodegenerative markers, longevity-associated genes, and medically actionable pharmacogenomic markers.

This analysis is designed for whole-genome or clinical-grade sequencing data rather than consumer genotyping files such as 23andMe alone.

You can add genome sequencing at checkout if you do not already have qualifying data available.

Yes. NeuroAge's current science and FAQ materials describe pharmacogenomic genes and disease-risk areas beyond Alzheimer's, including cardiovascular, bone, cancer, eye, and immune-related categories.

Put inherited risk and resilience into clearer context

Review APOE, polygenic risk, broader neurodegenerative and disease risks, and personalized recommendations in one genetics-focused product.